The client, a large biotech company, was seeking opportunities to strengthen its portfolio and drive the development of therapies for an oncology indication with a high unmet need.
The client sought to develop a tailored BD framework to assess assets in development that might be attractive “targets” to enhance its portfolio. Given that the therapeutic area of interest was quickly evolving and that other key players were likely interested in these assets, rapid development and alignment on this framework was essential.
Leveraging Prescient’s insights into market and competitive intelligence, we conducted an exhaustive review of the oncology treatment landscape and pipeline to identify the “universe” of potential assets for consideration.
Working in close collaboration with the client’s functional team (business development, R&D, etc.), we developed a BD framework to evaluate assets against key criteria, including the strength of the clinical profile and BD feasibility.
This framework was utilized to yield a short list of assets for consideration to help the client advance through the due diligence process.
Results and Solutions
The Prescient team moderated a cross-functional workshop to pressure-test the BD framework with an existing pool of assets to assess the potential and prioritize five oncology assets of interest.
By the end of this engagement, the client team aligned on the BD framework and a short list of assets for potential partnership consideration.